- Conditions
- Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Recurrent Small Cell Lung Cancer (SCLC), Tumors Metastatic to Brain, Metastatic Breast Cancer (mBC)
- Interventions
- Pegylated Irinotecan
- Drug
- Lead sponsor
- Joel Neal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)
- Interventions
- Itacitinib, erlotinib, placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Ogden, Utah
- Conditions
- Asthma
- Interventions
- Omalizumab, Placebo, Fluticasone
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
- Conditions
- Invasive Mechanical Ventilation
- Interventions
- Artificial Intelligence-based Decision support
- Other
- Lead sponsor
- Technische Universität Dresden
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 318,542 participants
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Pulmonary Infections, Pseudomonas Aeruginosa in Cystic Fibrosis
- Interventions
- TBM100
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Denver, Colorado • Jacksonville, Florida + 16 more
- Conditions
- Asthma
- Interventions
- Symbicort pMDI, Budesonide pMDI
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 59
- States / cities
- Hoover, Alabama • Montgomery, Alabama • Gilbert, Arizona + 56 more
- Conditions
- Dermatitis, Chronic
- Interventions
- clobetasol propionate 0.05%, Vehicle / Placebo
- Drug
- Lead sponsor
- Stiefel, a GSK Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 10
- States / cities
- San Diego, California • Boynton Beach, Florida • West Palm Beach, Florida + 6 more
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Pembrolizumab/Vibostolimab Co-Formulation, Saline placebo, Etoposide, Cisplatin, Atezolizumab, Carboplatin
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 11
- States / cities
- Mobile, Alabama • Los Angeles, California • Boca Raton, Florida + 7 more
- Conditions
- Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm, Melanocytoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
- Procedure · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cigarette Smoker, Current Smoker, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Best Practice, Biospecimen Collection, Laboratory Biomarker Analysis, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration, Smoking Cessation Intervention
- Other · Procedure · Behavioral
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Immunosuppression, COVID-19
- Interventions
- NVX-CoV2372
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Tarceva, carboplatin, paclitaxel
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 38
- States / cities
- Alhambra, California • Bakersfield, California • Concord, California + 31 more
- Conditions
- Recurrent Small Cell Lung Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Pegylated Irinotecan, Pharmacological Study
- Other · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 3
- States / cities
- Buffalo, New York • Rochester, New York
- Conditions
- COVID-19 Pandemic
- Interventions
- Connect2Test
- Behavioral
- Lead sponsor
- University of Oregon
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 349 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- Asthma
- Interventions
- Fluticasone
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Asthma
- Interventions
- epinephrine inhalation aerosol, Placebo
- Drug
- Lead sponsor
- Amphastar Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 33
- States / cities
- Costa Mesa, California • Los Angeles, California • Mission Viejo, California + 30 more
- Conditions
- Asthma
- Interventions
- Fluticasone Propionate (FP)
- Drug
- Lead sponsor
- Dey
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Rock Hill, South Carolina
- Conditions
- Congenital Heart Defects, Dysfunctional Right Ventricular Outflow Tract Conduits
- Interventions
- Transcatheter Pulmonary Valve replacement
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 5
- States / cities
- Miami, Florida • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Herpes Zoster
- Interventions
- HZ/su, Flu D-QIV, mRNA-1273
- Biological · Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,013 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 46
- States / cities
- Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
- Conditions
- Misinformation, Vaccine Hesitancy, Anxiety, Depression, COVID-19
- Interventions
- Attitudinal inoculation, Cognitive-behavioral therapy-informed intervention, Conventional public health messaging
- Behavioral
- Lead sponsor
- City University of New York, School of Public Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Interventions
- Qutenza (8% capsaicin)
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- MTX-463, Placebo
- Biological · Other
- Lead sponsor
- Mediar Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 23 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- REGN4659, Cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Grand Rapids, Michigan • Charlotte, North Carolina + 3 more
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer
- Interventions
- Etrumadenant, Zimberelimab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more